ERAS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of ...
Faruqi & Faruqi, LLP is investigating potential claims against Erasca, Inc. (ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The investigation stems from allegations that Erasca made false or misleading statements regarding its drug candidate ERAS-007, specifically concerning its preclinical data and comparison to a competitor's product, leading to significant stock price drops. Investors are encouraged to contact the firm by the August 10, 2026 deadline to discuss their legal rights and potentially serve as lead plaintiff in a class action lawsuit.
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged violations of federal securities laws. The lawsuit claims that Erasca made false and misleading statements regarding ERAS-0015's preclinical data and its comparisons to Revolution Medicines, Inc. Shareholders who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to join the lawsuit and have until August 10, 2026, to request to be appointed as lead plaintiff.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of Erasca, Inc. to join a class action lawsuit alleging securities fraud. The lawsuit claims that Erasca made false and misleading statements regarding its preclinical data for ERAS-0015, which was improperly compared to Revolution Medicines, Inc. and put the company at risk of patent violations. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, and suffered losses, have until August 10, 2026, to contact the firm.
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
Investors in Erasca, Inc. (NASDAQ:ERAS) who suffered losses have until August 10, 2026, to apply to be a lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that Erasca made false and misleading statements about its oncology drug candidate, ERAS-0015, including improper comparisons to a competitor's drug and failure to disclose patent and trade secret disputes. Following disclosures of a patent infringement claim and a patient death during clinical trials, Erasca's stock price significantly declined.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc.
The Rosen Law Firm reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock during the period of January 14, 2025, to April 26, 2026, about the August 10, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements regarding their lead oncology drug candidate, ERAS-0015, particularly concerning comparisons to a competitor's drug. Investors who bought Erasca stock during the Class Period may be entitled to compensation.
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
Kirby McInerney LLP is reminding investors of Erasca, Inc. (NASDAQ: ERAS) that they have until August 10, 2026, to seek the lead plaintiff role in a securities fraud class action lawsuit. The lawsuit alleges that Erasca made false and misleading statements about its oncology drug candidate, ERAS-0015, including improper comparisons to a competitor's drug and failure to disclose a patent dispute and a patient death during preliminary clinical trials. These disclosures led to significant drops in Erasca's stock price.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors in Erasca, Inc. (ERAS) of a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product's preclinical data, specifically concerning improper comparisons and potential patent violations. Investors who suffered losses during the class period (January 14, 2025, to April 26, 2026) have until August 10, 2026, to request to be appointed as lead plaintiff.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Erasca, Inc. (ERAS) for alleged securities fraud, encouraging investors who purchased securities between January 14, 2025, and April 26, 2026, to contact the firm. The lawsuit claims Erasca made false and misleading statements regarding its preclinical data for ERAS-0015, specifically concerning improper comparisons and a lack of basis for optimistic statements, which allegedly led to investor damages. Investors have until August 10, 2026, to participate and potentially lead the lawsuit.
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
Hagens Berman is investigating a securities class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) following a significant stock drop. The lawsuit alleges Erasca misled investors regarding its ERAS-0015 drug, particularly concerning intellectual property and patient safety, after Revolution Medicines accused Erasca of patent infringement and a patient died post-ERAS-0015 treatment. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial losses, are encouraged to contact Hagens Berman by the August 10, 2026, lead plaintiff deadline.
INVESTOR ALERT: Erasca, Inc. (NASDAQ: ERAS) Investors with
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial losses, have until August 10, 2026, to seek appointment as lead plaintiff. The lawsuit claims that Erasca made misleading statements regarding its drug ERAS-0015, particularly concerning preclinical data, potential patent infringement, and trade secret misappropriation, which led to significant stock price drops.
ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is reminding stockholders of Erasca, Inc. (NASDAQ: ERAS) that a class action lawsuit has been filed against the company. The lawsuit alleges that Erasca failed to disclose that its ERAS-0015 preclinical data was based on improper comparisons and risked violating patent and trade secret protections. Shareholders who purchased Erasca securities between January 14, 2025, and April 26, 2026, may be eligible to participate and have until August 10, 2026, to submit their papers to the court.
ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca failed to disclose that its preclinical data for ERAS-0015 was based on improper comparisons and risked violating patent and trade secret protections held by Revolution Medicines, Inc. Erasca's stock price fell significantly after Revolution Medicines, Inc. sent a letter alleging patent infringement and trade secret misappropriation.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, of the August 10, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements regarding its oncology drug candidate, ERAS-0015, improperly comparing it to a competitor's drug and failing to disclose material information. Investors are encouraged to join the class action to seek compensation.
Is Erasca’s (ERAS) Shift Into Russell Growth Indexes Reframing Its Core Investment Story?
Erasca, Inc. (ERAS) was recently reclassified from Russell value-oriented indexes to growth benchmarks, a move that aligns with its clinical-stage oncology focus and pipeline-driven valuation. This shift might alter its shareholder base and trading patterns, but doesn't change fundamental catalysts like trial results or financing needs. Investors are advised to consider the company's short cash runway and differing fair value estimates when evaluating its prospects.
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) and its officers. The lawsuit alleges that Erasca made false and misleading statements regarding ERAS-0015's preclinical data, specifically concerning improper comparisons and potential patent violations. Investors who suffered losses between January 14, 2025, and April 26, 2026, have an opportunity to lead the class action and are encouraged to contact the firm.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, about the August 10, 2026, deadline to serve as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements about its oncology drug candidate, ERAS-0015, specifically regarding its comparison to a competitor's drug and the failure to disclose related patent and trade secret issues. Investors who bought Erasca stock during this period may be entitled to compensation.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock during the period of January 14, 2025, to April 26, 2026, about the August 10, 2026, deadline to seek appointment as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Erasca, Inc. made false statements regarding its lead oncology drug candidate, ERAS-0015, by improperly comparing it to a competitor's drug and failing to disclose potential patent and trade secret issues. Investors who suffered damages may be entitled to compensation.
INVESTOR ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for investors who purchased common stock between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, specifically concerning its preclinical data's basis and the risks of infringing patent protections. Investors with substantial losses are encouraged to seek appointment as lead plaintiff by August 10, 2026.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Erasca, Inc. (NASDAQ: ERAS) for allegedly violating federal securities laws by failing to disclose material information regarding its ERAS-0015 product between January 14, 2025, and April 26, 2026. Investors who suffered losses during this period have until August 10, 2026, to request to be appointed as lead plaintiff. KSF, a prominent securities litigation firm, is encouraging affected investors to contact them for more information.
FinancialContent - Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC ("KSF") has announced a class action securities lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged violations of federal securities laws. The lawsuit claims that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product's preclinical data during the Class Period from January 14, 2025, to April 26, 2026. Investors who suffered losses have until August 10, 2026, to apply to be appointed as lead plaintiff.
ERAS - Erasca Inc Revenue Breakdown
This article provides a detailed financial breakdown of Erasca Inc. (ERAS), including its market capitalization, sales, income, various financial ratios, and stock performance metrics. It highlights key data points such as the stock's last close at $17.92, a significant year-to-date performance of 381.72%, and insider/institutional ownership figures. The company's lack of sales revenue is also noted.
ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP reminds investors of Erasca, Inc. (NASDAQ: ERAS) about an upcoming class action lawsuit deadline of August 10, 2026. The lawsuit alleges that Erasca made false and misleading statements regarding preclinical comparisons of its lead drug candidate, ERAS-0015, to Revolution Medicines' RMC-6236, failing to disclose intellectual property risks. This alleged misrepresentation led to significant stock losses for investors, who are now encouraged to seek to recover their losses.
ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10,
Bernstein Liebhard LLP reminds Erasca, Inc. (NASDAQ: ERAS) investors that they have until August 10, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Erasca made false and misleading statements between January 14, 2025, and April 26, 2026, leading to artificially inflated stock prices and investor losses. Shareholders who owned ERAS shares during this period and suffered losses are encouraged to act promptly.
Erasca (NASDAQ: ERAS) investors back board slate and KPMG auditor
Erasca, Inc. stockholders re-elected three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—to three-year terms at their annual meeting on June 26, 2026. They also ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. A strong quorum was established with 266,073,906 shares represented out of 310,965,971 eligible shares.
Erasca, Inc. Notice of August 10, 2026 Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors in Erasca, Inc. (NasdaqGS: ERAS) of a class action securities lawsuit. The lawsuit seeks to recover losses for investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, alleging that the company and its executives failed to disclose material information regarding the ERAS-0015 product's preclinical data. Investors have until August 10, 2026, to apply for lead plaintiff status.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice to investors in Erasca, Inc. (NASDAQ: ERAS) regarding a class action securities lawsuit. Investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, are part of the class, with an application deadline of August 10, 2026, to request lead plaintiff status. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product's preclinical data and its potential violation of patent and trade secret protections.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) alleging that the company made false and misleading statements about its ERAS-0015 drug, specifically regarding preclinical data comparisons that potentially violated patent and trade secret protections. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026. The firm operates on a contingency fee basis, seeking to recover damages for affected investors.
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Erasca, Inc. (ERAS), offering shareholders who incurred losses between January 14, 2025, and April 26, 2026, the opportunity to become lead plaintiffs. The lawsuit alleges that Erasca made misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons and risked violating patent protections. Investors are encouraged to contact the firm by the August 10, 2026 deadline to participate or learn more about their rights.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud. The lawsuit claims that Erasca made false and misleading statements regarding its preclinical data for ERAS-0015, which purportedly infringed on patents and lacked a proper basis for optimistic claims. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to contact the firm by August 10, 2026, to potentially lead the lawsuit.
Erasca (ERAS) director Alexander Casdin awarded 29,888 stock options at $16.01 strike
Erasca, Inc. director Alexander W. Casdin was granted 29,888 stock options with an exercise price of $16.01 per share. These options, which incentivize long-term board involvement, will vest 100% on June 26, 2027, provided his continuous service, and expire on June 26, 2036. This transaction is considered a neutral, standard compensation practice and does not involve an open-market purchase or sale of shares.
Form 4 Erasca Inc For: 29 June By Investing.com
This article provides details of a Form 4 filing for Erasca Inc., dated June 29. It notes the stock symbol ERAS and references its performance with a +14.24% change. The content primarily consists of financial market data and unrelated trending articles, suggesting the Form 4 document itself is not fully presented in the provided text.
Erasca (NASDAQ: ERAS) director receives 29,888 stock options vesting in 2027
Erasca, Inc. director James Arthur Bristol was granted 29,888 stock options with an exercise price of $16.01 per share as part of his compensation. These options, granted at no cost, will vest 100% on June 26, 2027, contingent on his continued service to the company, and will expire on June 26, 2036. This transaction is a compensation award, not an open-market purchase or sale of shares.
Erasca (NASDAQ: ERAS) director receives stock options for 29,888 shares
Erasca, Inc. director Julie Hambleton was granted stock options for 29,888 shares of common stock at an exercise price of $16.01 per share. These options are part of her compensation, vest 100% on June 26, 2027, and expire on June 26, 2036. This transaction is a compensation-related award, not an open-market purchase or sale.
[Form 4] Erasca, Inc. Insider Trading Activity
Erasca, Inc. director Jean I. Liu was granted 29,888 stock options on June 26, 2026, with an exercise price of $16.01 per share, vesting entirely on June 26, 2027. This transaction is considered equity compensation rather than a market purchase or sale. The filing indicates Liu now holds options for 29,888 shares, and the options expire on June 26, 2036.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice to investors in Erasca, Inc. (NASDAQ: ERAS) regarding a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information between January 14, 2025, and April 26, 2026, concerning preclinical data for their ERAS-0015 product. Investors who suffered losses during this period have until August 10, 2026, to apply for lead plaintiff status.
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2500 Growth Benchmark
Erasca, Inc. (NasdaqGS: ERAS), a clinical-stage precision oncology company, has been added to the Russell 2500 Growth Benchmark. This move comes as the company also saw significant activity in other Russell indices, and its stock has experienced notable positive changes year-to-date and over the last five days. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, with its lead product candidate, naporafenib, currently in a pivotal Phase III trial.
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Erasca, Inc. (ERAS) shareholders who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Erasca made misleading statements concerning its drug candidate ERAS-0015, which was accused of patent infringement and trade secret misappropriation by Revolution Medicines, and also involved a patient death during preliminary Phase 1 clinical trials, causing significant stock price drops. Investors have until August 10, 2026, to file a lead plaintiff motion.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS
Levi & Korsinsky, LLP is alerting investors of Erasca, Inc. (NASDAQ: ERAS) about a securities class action lawsuit against the company and its two senior executives, Jonathan Lim and David Chacko. The lawsuit alleges that Lim and Chacko certified misleading financial statements regarding ERAS-0015, while the company raised $258.8 million from investors. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to apply for lead plaintiff appointment by August 10, 2026.
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2000 Growth Benchmark
Erasca, Inc. (NasdaqGS: ERAS) has been added to the Russell 2000 Growth Benchmark, as announced on June 29, 2026. This news follows several other index adjustments for the company, including being added to the Russell 2500 Growth and Russell 3000E Growth benchmarks, while being dropped from the Russell Microcap Value, Russell 2000 Value, Russell 3000E, and Russell Microcap indexes. Erasca is a clinical-stage precision oncology company focusing on therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 3000E Growth Benchmark
Erasca, Inc. (NasdaqGS: ERAS), a precision oncology company, has been added to the Russell 3000E Growth Benchmark. The company focuses on developing therapies for RAS/MAPK pathway-driven cancers, with a pipeline that includes a clinical-stage pan-RAF inhibitor and other promising programs. Erasca's stock performance shows significant growth, with a 330.38% increase year-to-date and a 17.12% increase since January 1st.
Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Securities Class Action Lawsuit - Contact Before Deadline on August 7, 2026 for Leadership Role
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit stems from allegations that Erasca's ERAS-0015 product infringed on a Revolution Medicines, Inc. patent and involved trade secret misappropriation, leading to an almost 11% stock drop. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 7, 2026.
Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
ClaimsFiler is reminding investors who suffered losses over $100,000 in Erasca, Inc. (ERAS) to file lead plaintiff applications by August 10, 2026, in a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements regarding the preclinical data for their ERAS-0015 product, potentially violating patent and trade secret protections. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are affected.
ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS) regarding a securities class action lawsuit. Investors who purchased shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm, as the deadline to seek lead plaintiff appointment is August 10, 2026. The lawsuit alleges that Erasca made materially false or misleading statements regarding its ERAS-0015 preclinical data.
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Erasca, Inc. (NASDAQ: ERAS) on August 7, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made false and misleading statements regarding its drug ERAS-0015, particularly concerning improper comparisons with Revolution Medicines, Inc.'s product and potential patent infringement. Investors have until August 7, 2026, to move the court to serve as a lead plaintiff.
ERASCA CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.
A class action lawsuit has been filed against Erasca, Inc. (ERAS) by Bragar Eagel & Squire, P.C., alleging that Erasca made false and misleading statements regarding its ERAS-0015 drug, which is accused of infringing on a Revolution Medicines patent and misappropriating trade secrets. The lawsuit covers investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and a significant stock price drop followed the disclosure of Revolution Medicines' allegations. Investors have until August 10, 2026, to apply for lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) alleging that the company and its officers made false or misleading statements regarding ERAS-0015's preclinical data comparisons and patent risks. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, are encouraged to join the lawsuit by August 10, 2026, to potentially recover damages.
ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities ...
The Gross Law Firm has issued a deadline alert for investors of Erasca, Inc. (ERAS) to remind them of an upcoming deadline to register as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Erasca made materially false and/or misleading statements regarding its ERAS-007 data and patent protections. Shareholders who purchased ERAS shares between January 12, 2021, and April 22, 2026, are encouraged to contact the firm by August 1, 2026.
ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS) regarding a securities class action lawsuit. The complaint alleges that Erasca made materially false and/or misleading statements concerning ERAS-0015's preclinical data, potentially violating patent and trade secret protections. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm, with the lead plaintiff deadline set for August 10, 2026.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
Erasca, Inc. (ERAS) is facing a securities class action lawsuit following a significant drop in its stock price after two major disclosures. The company announced patent infringement allegations from Revolution Medicines and reported a patient death linked to its ERAS-0015 treatment. This news led to a 48% decline in Erasca's stock, resulting in a $2.8 billion market capitalization loss.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of Erasca, Inc. to join a class action lawsuit alleging securities fraud. The lawsuit claims that Erasca made false and misleading statements regarding its preclinical data on ERAS-0015, specifically an improper comparison to Revolution Medicines, Inc. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, and suffered losses are urged to contact the firm.
